ALAUNOS THERAPEUTICS INC
TCRTNASDAQTrading Snapshot
- Day Range
- $1.64 β $1.68
- 52-Week Range
- $0.72 β $4.50
- Volume (shares)
- 1,522
- Avg Volume (shares)
- β
- Shares Outstanding
- 3.6M
- Next Earnings
- 2027-03-29
Fundamentals Snapshot
- Annual Revenue
- $5,000
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 1397.2x
- EPS (TTM)
- $-1.82
- Dividend Yield
- β
- Dilution (1yr)
- +21.7%
ALAUNOS THERAPEUTICS INC
TCRTAbout ALAUNOS THERAPEUTICS INC
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates
News unavailable.